- Home
- KEY vs RPRX Comparison
KEY vs RPRX Comparison
Compare KEY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEY | RPRX |
|---|---|---|
| Founded | 1825 | 1996 |
| Country | United States | United States |
| Employees | 17883 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 19.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KEY | RPRX |
|---|---|---|
| Price | $20.68 | $47.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $22.46 | ★ $47.75 |
| AVG Volume (30 Days) | ★ 14.8M | 2.9M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.01% | 1.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $15.33 | $38.30 |
| Revenue Next Year | $6.04 | $4.80 |
| P/E Ratio | ★ $14.43 | $27.29 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $12.80 | $30.04 |
| 52 Week High | $23.35 | $49.06 |
Technical Indicators
Market Signals| Indicator | KEY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 58.36 |
| Support Level | $20.33 | $44.84 |
| Resistance Level | $21.25 | $47.86 |
| Average True Range (ATR) | 0.45 | 0.92 |
| MACD | 0.21 | 0.11 |
| Stochastic Oscillator | 98.49 | 61.20 |
Price Performance
Historical ComparisonAbout KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 15 states, but it is predominantly concentrated in its three largest markets: Ohio, New York, and Washington. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.